Algorithm to predict treatment outcomes in advanced cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to develop an algorithm that predicts treatment outcomes for patients with stage IV non-small cell lung cancer (NSCLC) and malignant melanoma. Patients will receive standard cancer treatments while providing blood samples and clinical data, which will be used to create and validate the prediction algorithm. The study seeks to identify metabolic pathways that may lead to improved therapeutic options, ultimately assisting physicians in making informed treatment decisions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Cancer patients with stage IV NSCLC or stage IV malignant melanoma
* Patient must have at least one measurable lesion and the relevant images in order to enable assessment of response
* ECOG PS - 0/1-2
* Normal hematologic, renal and liver function:

  1. Absolute neutrophil count higher than 1500/mm3
  2. Platelets count higher than 100,000/mm3
  3. haemoglobin higher than 9 g/dL
  4. Creatinine concentration ≤1.4 mg/dL, or creatinine clearance higher than 40 mL/min
  5. Total bilirubin lower than 1.5 mg/dL, ALT and AST levels ≤ 3 times above the upper normal limit.

Exclusion Criteria:

* Concurrent and/or other active malignancy that has required systemic treatment within 2 years of first dose of study drug
* Generalized impairment or mental incompetence that would render the patient unable to understand his/her participation in the study.

Where it's running

• Birmingham VAHCS
  Birmingham, Alabama, United States Recruiting
• Mayo Clinic
  Jacksonville, Florida, United States Recruiting
• University of Miami
  Miami, Florida, United States Recruiting
• Florida Cancer Specialist and Research Institute
  Orlando, Florida, United States Recruiting
• Protean Biodiagnosics
  Orlando, Florida, United States Recruiting
• Northwest Community Healthcare
  Rolling Meadows, Illinois, United States Recruiting

Study contacts

• Principal investigator: Alona Zer, MD — 003 Rambam Medical Center
• Study coordinator: Shani Raveh Shoval, Ph.D.
• Email: shani@oncohost.com
• Phone: 97248537554

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cemiplimab guided by ctDNA levels (PALACE)

  This study will see if starting adults with advanced (stage IIIB/C or IV) non-small cell lung cancer and PD-L1 ≥50% on cemiplimab, then using ctDNA and early scans to decide whether to add chemotherapy, can improve overall survival.

  Recruiting at 19 sites Phase 2 Fundación GECP · Alicante, Alicante and 19 other locations · NCT06917573

• Analyzing tumor DNA to predict response to cancer treatment in lung cancer patients

  This study is testing if measuring tumor DNA in the blood can help predict how well lung cancer patients respond to a specific treatment called Tyrosine Kinase Inhibitors.

  Recruiting Gene Solutions · Ho Chi Minh City · NCT06167460

• Using enhanced immune cells to treat specific types of lung cancer

  This study is testing a new treatment using special immune cells and a drug to see if it can help people with advanced lung cancer that has certain genetic changes and hasn’t improved with previous treatments.

  Recruiting Phase 1 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT05681780

• Infusion of IOV-4001 for advanced melanoma and lung cancer

  This study is testing a new treatment called IOV-4001 to see if it can help adults with advanced melanoma and lung cancer by targeting and killing their tumor cells.

  Recruiting at 10 sites Phase 1/2 Iovance Biotherapeutics, Inc. · Los Angeles, California and 10 other locations · NCT05361174

• Supportive care model for patients with advanced lung cancer

  This study is testing a new supportive care program for people with advanced lung cancer to see if it helps them feel less stressed and more confident about managing their condition compared to standard care.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT04900935

• New radiotherapy approach for advanced lung cancer

  This study is testing a new type of radiotherapy for patients with advanced lung cancer who can't have regular treatment to see if it can help them live longer and feel better.

  Recruiting Danish Lung Cancer Group · Aarhus · NCT03742687

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.